| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Akebia Therapeutics, Inc. (AKBA) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. AKBA is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.46M | $4.02M | - | |
| CFO | 320.0K | $371.2K | - | |
| Dir | 160.9K | $186.7K | - | |
| Dir | 129.5K | $150.2K | - | |
| VP | 119.0K | $138.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 3, 2017 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,554 | $14.26 | $22,156.47 | -1.4% | |
| Jul 3, 2017 | Nash Duane | Director | Sell | 990 | $14.27 | $14,127.30 | -4.0% | |
| Apr 3, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,401 | $9.18 | $12,857.68 | -1.3% | |
| Apr 3, 2017 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,556 | $9.18 | $14,280.19 | -1.4% | |
| Apr 3, 2017 | Nash Duane | Director | Sell | 991 | $9.20 | $9,119.28 | -3.9% | |
| Jan 3, 2017 | Nash Duane | Director | Sell | 1,980 | $10.46 | $20,711.00 | -7.2% | |
| Jan 1, 2017 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,810 | $10.49 | $18,987.99 | -2.1% | |
| Jan 1, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,629 | $10.49 | $17,089.19 | -2.3% | |
| Oct 3, 2016 | Nash Duane | Director | Sell | 1,981 | $8.96 | $17,746.00 | -6.7% | |
| Oct 1, 2016 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,556 | $8.95 | $13,933.67 | -1.8% |